$CGTX
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies
More Info: https://t.co/terb4IE2ze
Dr. James Galvin presented results from 2 Dementia with Lewy Bodies drug trials Zervimesine and Nexlamapimod. Both will go to phase 3. 🤞
@TheNewANA1
@NMNeurology#ANA2025
$CGTX presented a poster at #AAIC2025 showing that #zervimesine treatment in the Phase 2 'SHINE' study arrested further cognitive deterioration in mild-to-moderate #Alzheimers patients who had lower levels of plasma p-tau217 regardless of their MMSE scores.
Press Release: https://t.co/dp5srXh1Hi.
AAIC posters: https://t.co/GPWQeplX0K.
#Dementia #BiotechInnovation #ClinicalResearch #ClinicalTrial #biotech #HealthcareInnovation #Proteomics #BrainHealth #Biomarkers #AAIC2025 #AAIC25 #PrecisionMedicine #ENDALZ
$CGTX research team presented two posters at #AAIC2025 exploring the mechanism that underlies the impact of zervimesine in #Alzheimers disease. An analysis of cerebrospinal fluid (CSF) from Phase 2 'SHINE' participants who had lower levels of p-tau217 identified proteins that correlate to zervimesine's impact on cognitive function. Find the poster here: https://t.co/GPWQeplpbc
#Dementia #BiotechInnovation #ClinicalResearch #ClinicalTrial #biotech #AlzheimersDisease #HealthcareInnovation #Proteomics #BrainHealth #Biomarkers #AAIC25 #zervimesine
Yesterday $CGTX reported financial results for the second quarter ended June 30, 2025. Read the #pressrelease here: https://t.co/K3LOKlzhXW
Business highlights for the quarter include an end-of-Phase 2 meeting with #FDA for #AlzheimersDisease; enrollment milestone in early #Alzheimers trial; topline Phase 2 #dryAMD results; expanded access program for DLB and more.
#BiotechInnovation #ClinicalResearch #ClinicalTrial #HealthcareInnovation #LewyBodyDementia #LewyStrong #DementiaWithLewyBodies #Dementia #DementiaCare #DementiaSupport
$CGTX received the #FDA end-of-Phase 2 meeting minutes. Read the #pressrelease here: https://t.co/axpYroKtmX
The agency confirmed that the proposed design of the Phase 3 program may support a New Drug Application for #zervimesine (CT1812) as a treatment for #Alzheimers disease.
#BiotechInnovation #ClinicalResearch #ClinicalTrial #HealthcareInnovation #AlzheimersDisease #BrainHealth #Dementia #DementiaCare #DementiaSupport
$CGTX announced that the Phase 2 ‘START’ Study in early #Alzheimers disease has reached the 75% enrollment mark. Read the #pressrelease here: https://t.co/7TaevsaJai
Great world news coming in, and the markets are reacting promisingly. $Escape is rolling out new features, and there's a nice chance to DCA and secure some really nice profits.
#WAGMI#LFG#PUMP#BSC#BSCCHAIN#BNB#FA
$Escape will be introducing
*Rev Share for holders of the token
*More partnerships with other projects
*More listings, and working toward CEX's
This is a long term highly motivated team with goals oriented toward passive income for years, not months.
#BNB#BNBCHAIN#BSC#WAGMI #PUMP #LFG #ESCAPETHEWAGECAGE
Dip on the chart, but the liquidity pool that generates revenue is growing nicely. The team and dev are still working, and are going to be introducing rev share.
We have also partnered with a great Solana based project, and have an upcoming competition
https://t.co/s0Gw9vgx0w